MDT

98.5

+2.11%↑

146.08

-0.25%↓

VEEV

218.2

-4.44%↓

HQY

85.69

+1.95%↑

NEOG

9.39

+2.4%↑

MDT

98.5

+2.11%↑

146.08

-0.25%↓

VEEV

218.2

-4.44%↓

HQY

85.69

+1.95%↑

NEOG

9.39

+2.4%↑

MDT

98.5

+2.11%↑

146.08

-0.25%↓

VEEV

218.2

-4.44%↓

HQY

85.69

+1.95%↑

NEOG

9.39

+2.4%↑

MDT

98.5

+2.11%↑

146.08

-0.25%↓

VEEV

218.2

-4.44%↓

HQY

85.69

+1.95%↑

NEOG

9.39

+2.4%↑

MDT

98.5

+2.11%↑

146.08

-0.25%↓

VEEV

218.2

-4.44%↓

HQY

85.69

+1.95%↑

NEOG

9.39

+2.4%↑

Strona główna・Stock List・Amicus Therapeutics Inc

Amicus Therapeutics Inc

Closed

SectorHealthcare

14.36 0.28

Buy Sell

Overview

Share price change

24h

Current

Min

14.31

Max

14.36

Key metrics
By Trading Economics
Income	42M 17M
Sales	14M 169M
Profit margin	10.237
Employees	499
EBITDA	54M 48M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	-0.21% downside

Dividends
By Dow Jones
Next Earnings	18 lut 2026

Market Stats
By TradingEconomics
Market Cap	2.1B 4.4B
Previous open	14.08
Previous close	14.36

News Sentiment

By Acuity

84%

16%

340 / 361 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

5.925 / 7.38 Support & Resistance

Amicus Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

19 gru 2025, 14:38 UTC

Earnings

Hot Stocks

Stocks to Watch Friday: Nike, Oracle, FedEx, Sony -- WSJ

Peer Comparison

Price change

Amicus Therapeutics Inc Forecast

Price Target

By TipRanks

-0.21% downside

12 Months Forecast

Average 14.25 USD -0.21%

High 19 USD

Low 11 USD

Based on 10 Wall Street analysts offering 12 month price targets forAmicus Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

10 ratings

Buy

Hold

Sell

Based on 10 analysts giving stock ratings to Amicus Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

5.925 / 7.38Support & Resistance

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

340 / 361 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Amicus Therapeutics Inc

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.